Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi
- PMID: 16495251
- PMCID: PMC1426453
- DOI: 10.1128/AAC.50.3.917-921.2006
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi
Abstract
We have compared the activities of posaconazole and other currently available antifungal agents against a collection of 3,378 clinical isolates of yeasts and filamentous fungi. A total of 1,997 clinical isolates of Candida spp., 359 of other yeast species, 697 strains of Aspergillus spp., and 325 nondermatophyte non-Aspergillus spp. were included. The average geometric means of the MICs of agents that were tested against Candida spp. were 0.23 microg/ml for amphotericin B, 0.29 microg/ml for flucytosine, 0.97 microg/ml for fluconazole, 0.07 microg/ml for itraconazole, 0.04 microg/ml for voriconazole, 0.15 microg/ml for caspofungin, and 0.03 microg/ml for posaconazole. Voriconazole and posaconazole were active in vitro against the majority of isolates, with resistance to fluconazole and itraconazole, and against Cryptococcus neoformans and other Basidiomycota yeasts. Posaconazole was the most active of antifungal agents tested against Aspergillus spp., with an average geometric mean of 0.10 microg/ml. It was active against Paecilomyces spp., Penicillium spp., Scedosporium apiospermum, and some black fungi, such as Alternaria spp. Multiresistant filamentous fungi, such as Scedosporium prolificans, Scopulariopsis brevicaulis, and Fusarium solani, were also resistant to voriconazole, caspofungin, and posaconazole. Amphotericin B and posaconazole were found to be active against most of the Mucorales strains tested. Posaconazole and currently available antifungal agents exhibit a potent activity in vitro against the majority of pathogenic fungal species.
Similar articles
-
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.Rev Iberoam Micol. 2003 Dec;20(4):121-36. Rev Iberoam Micol. 2003. PMID: 15456349 Review.
-
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.J Clin Microbiol. 2003 Aug;41(8):3623-6. doi: 10.1128/JCM.41.8.3623-3626.2003. J Clin Microbiol. 2003. PMID: 12904365 Free PMC article.
-
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. doi: 10.1128/AAC.00163-06. Antimicrob Agents Chemother. 2006. PMID: 16723559 Free PMC article.
-
Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.Antimicrob Agents Chemother. 2008 Oct;52(10):3637-41. doi: 10.1128/AAC.00662-08. Epub 2008 Aug 11. Antimicrob Agents Chemother. 2008. PMID: 18694949 Free PMC article.
-
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.Mycopathologia. 2001;150(3):101-15. doi: 10.1023/a:1010954803886. Mycopathologia. 2001. PMID: 11469757 Review.
Cited by
-
Saprochaete/Magnusiomyces: identification, virulence factors, and antifungal susceptibility of a challenging rare yeast.Braz J Microbiol. 2024 Mar;55(1):41-49. doi: 10.1007/s42770-024-01248-7. Epub 2024 Jan 17. Braz J Microbiol. 2024. PMID: 38233642
-
Successful Use of Fosmanogepix for Treatment of Rare Highly Resistant Cutaneous Fusariosis in a Pediatric Patient With STAT3 Hyper-Immunoglobulin E Syndrome and End-Stage Kidney Disease.Open Forum Infect Dis. 2023 May 23;10(6):ofad285. doi: 10.1093/ofid/ofad285. eCollection 2023 Jun. Open Forum Infect Dis. 2023. PMID: 37305844 Free PMC article.
-
Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients.Pathogens. 2023 May 10;12(5):694. doi: 10.3390/pathogens12050694. Pathogens. 2023. PMID: 37242364 Free PMC article. Review.
-
Non-Aspergillus Hyaline Molds: A Host-Based Perspective of Emerging Pathogenic Fungi Causing Sinopulmonary Diseases.J Fungi (Basel). 2023 Feb 6;9(2):212. doi: 10.3390/jof9020212. J Fungi (Basel). 2023. PMID: 36836326 Free PMC article. Review.
-
Fusarium proliferatum-induced chronic lip ulcer: successful treatment with itraconazole: a case report.J Med Case Rep. 2022 Sep 30;16(1):346. doi: 10.1186/s13256-022-03575-5. J Med Case Rep. 2022. PMID: 36175913 Free PMC article.
References
-
- Cacciapuoti, A., D. Loebenberg, E. Corcoran, F. Menzel, Jr., E. L. Moss, Jr., C. Norris, M. Michalski, K. Raynor, J. Halpern, C. Mendrick, B. Arnold, B. Antonacci, R. Parmegiani, T. Yarosh-Tomaine, G. H. Miller, and R. S. Hare. 2000. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44:2017-2022. - PMC - PubMed
-
- Carrillo-Munoz, A. J., G. Quindos, M. Ruesga, R. Alonso, O. del Valle, J. M. Hernandez-Molina, P. McNicholas, D. Loebenberg, and P. Santos. 2006. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J. Antimicrob. Chemother. 55:317-319. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous